Viking Therapeutics

VKTXPhase 3

Viking Therapeutics leverages its expertise in metabolism to develop innovative therapies for metabolic and endocrine disorders. The company's most advanced program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 trials for obesity, with promising Phase 2 data showing significant weight reduction. Viking is also developing VK2809 for lipid disorders and maintains a broader pipeline including VK0214 and VK5211, positioning itself as a key player in the competitive metabolic disease space.

Market Cap

$3.7B

Focus

Small Molecules

VKTX · Stock Price

USD 32.33+29.19 (+929.62%)

Historical price data

AI Company Overview

Technology Platform

Hormone receptor pharmacology focusing on dual GLP-1/GIP receptor agonism and selective thyroid hormone receptor beta agonism for metabolic disorders.

Pipeline Snapshot

9 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
VK2735	Weight Loss	Phase 3
VK2735	Weight Loss	Phase 3
VK2809 + Placebos	NASH - Nonalcoholic Steatohepatitis	Phase 2
VK5211 + Placebo	Hip Fractures	Phase 2
Placebo + VK2735	Weight Loss	Phase 2

Funding History

Total raised: $155M

PIPE$125MRA Capital ManagementFeb 15, 2024

IPO$30MLeerink PartnersMay 14, 2015

Opportunities

Viking has significant opportunities in the massive obesity drug market with its dual GLP-1/GIP agonist VK2735, particularly if it can demonstrate competitive efficacy and safety.

The development of an oral formulation could provide additional differentiation and market penetration.

Expansion into related metabolic disorders and potential partnerships with larger pharma companies represent additional growth avenues.

Risk Factors

Key risks include clinical trial failures in Phase 3 studies, intense competition from established players like Novo Nordisk and Eli Lilly, regulatory hurdles for approval, and challenges in commercializing products in crowded markets.

As a pre-revenue company, Viking also faces financial risks related to funding ongoing clinical development.

Competitive Landscape

Viking competes in the obesity market against Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound), and in metabolic disorders against various companies developing lipid-modifying therapies. Differentiation may come from VK2735's dual mechanism, oral formulation development, and potentially improved tolerability profiles compared to existing therapies.

Publications

Patents

Pipeline